• Investors 'should be very content' with recent Fed rate cuts
    Yahoo Finance Video

    Investors 'should be very content' with recent Fed rate cuts

    Yahoo Finance's Alexis Christoforous, Brian Sozzi and Jared Blikre discuss what's moving the markets with PNC Chief Investment Strategist Amanda Agati around Thursday's opening bell.

  • 6 Cheap Stocks With Low Price-Sales Ratios
    GuruFocus.com

    6 Cheap Stocks With Low Price-Sales Ratios

    Walt Disney tops the list Continue reading...

  • A Trio of Strong Performers
    GuruFocus.com

    A Trio of Strong Performers

    Facebook tops the list of highly profitable companies Continue reading...

  • UnitedHealth to Offer Medicare Advantage Plan in Bay Area
    Zacks

    UnitedHealth to Offer Medicare Advantage Plan in Bay Area

    UnitedHealth's (UNH) new Medicare Advantage Plan to serve Medicare beneficiaries in Bay Area.

  • Stock Market News For Sep 20, 2019
    Zacks

    Stock Market News For Sep 20, 2019

    Benchmarks mostly closed in the green on Thursday on upbeat U.S. housing market as well as gains in Microsoft.

  • P&G CEO Taylor, activist investor Peltz laugh off proxy battle as stock soars
    American City Business Journals

    P&G CEO Taylor, activist investor Peltz laugh off proxy battle as stock soars

    Procter & Gamble CEO David Taylor and Nelson Peltz, the activist investor who waged the biggest proxy battle ever before being invited to join the board of P&G; in 2018, laughed off past disagreements over strategy as the company’s stock continued to impress.

  • Barrons.com

    Kellogg and 5 Other Staples Stocks for Dividends and a Bit of Growth

    Consumer-staples stocks have outperformed the broader market over the past year, but cooler returns lately have made stocks like Coca-Cola and Kellogg a little more attractive for income investors.

  • Trian and P&G highlight activist-corporate collaboration after 'fog of war'
    Reuters

    Trian and P&G highlight activist-corporate collaboration after 'fog of war'

    Eighteen months after officially burying the hatchet in one of America's most bitter proxy contests, Procter & Gamble Co CEO David Taylor and billionaire investor Nelson Peltz proclaimed their mutual respect on Thursday, underscoring how activists and corporations can end up working collaboratively. Sitting next to each other on a hotel stage in New York at the CNBC Institutional Investor Delivering Alpha Conference, the men brushed away the acrimony of two years ago when Peltz' Trian Partners was battling P&G over its strategy and asking for a board seat. "That was the fog of war," Peltz said, dismissing the rough comments P&G had made about the veteran activist who works to present himself as a partner who can offer constructive advice rather than a corporate raider intent on breaking up companies.

  • Ironwood Amends Linzess Agreement with AstraZeneca in China
    Zacks

    Ironwood Amends Linzess Agreement with AstraZeneca in China

    Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.

  • Benzinga

    11 Most Aggressively Shorted Stocks

    Traders also look at the activity of short sellers for trading opportunities. Sometimes, stocks with a large amount of short selling activity could be potential candidates for short squeezes. Other times, ...

  • FDA Warns About Safety of Breast Implant: 3 Stocks at Risk
    Zacks

    FDA Warns About Safety of Breast Implant: 3 Stocks at Risk

    As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.

  • American City Business Journals

    Former P&G executive to help guide big data firm

    A former vice chairman of Procter & Gamble Co. has joined the board of IRI, a global firm focused on big data, predictive analytics and forward-looking insights for consumer, retail and media companies.

  • InvestorPlace

    5 Undervalued Stocks to Buy

    [Editor's note: This story was previously published in February 2019. It has since been updated and republished.]Overall, the stock market continued its huge improvement throughout 2019, compared to where it ended in 2018; it has been a complete turnaround from last year's drop, when stocks entered bear-market territory. Markets started slipping again in the month of August, traded in a range, and then turned to rally to new all-time highs.But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have done so well. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy; it has just become a little trickier to find them amid all the flashy comeback stories.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo find the best stocks to buy now, disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the back burner for later. Among such stocks, companies that got left out of the rally are the most compelling. Even better, some of the best undervalued stocks to buy are those that dropped by double-digit percentages during the current rally.Why is that?Stocks that have already priced in current and possible negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower. * 8 Dividend Stocks to Buy for a Recession With all of that in mind, here are five undervalued stocks to buy that aren't as scary as they seem. Sony (SNE)Investors who held Sony (NYSE:SNE) stock through the Q2 2019 earnings report posted on July 30 enjoyed the rally that followed. The stock rose from $54.50 to nearly $60 recently. The company reported revenue falling just 1.4% year-over-year but operating income rose 18%, up 35.9 billion yen (US $332.2 million).Now that Sony is trading at yearly highs, investors need not sell the stock just yet.Why not?In a Sept 13 report, video game sales in August fell again by 18%, to $666 million. The industry could not count on any big game title hits to lift monthly sales. But the gaming sector has some hope ahead. When Sony's Playstation 5 arrives, SNE will have more power than ever. Though the PS5 release will release no sooner than mid-2020, 8K support and game refreshes should give Sony another boost in revenue when the time comes.Sony faced a few headwinds in the quarter. Contributions from first-party software titles fell. Sales of non-first party titles declined. But PS4 hardware sales rose, as did network service sales, including sales of PlayStation Plus. Celestica (CLS)In July, Celestica (NYSE:CLS) reported weak Q2/2019 results that sent the stock to as low as $6 by the end of August. Celestica reported revenue of $1.45 billion, down 15% from last year. Its aerospace and defense segment etched out a 2% revenue growth in the period, offset by a 23% decline in revenue from its Connectivity and Cloud Solutions (CCS) division. Adjusted EPS was $0.12, down from $0.29 last year. In September, the stock staged a major rally.The company supplies equipment in ATS -- aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line.Celestica stock is still an undervalued play worth considering. The stock may underperform a while longer and risks disappointing investors. Again. Consider watching the stock's next earnings report before committing to a position. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Celestica stock is an undervalued stock worth considering. AbbVie (ABBV)Back when I first wrote this list of undervalued stocks, Allergan (NYSE:AGN) was the pick in this slot. And it paid off. Investors buying Allergan at the start of 2019 may have made up to $50 a share, peak to trough. In June, the stock fell below $115, only to peak at around $165 in July when my new pick, AbbVie (NYSE:ABBV), agreed to buy out the firm for $63 billion. AbbVie's rationale for acquiring Allergan is two-fold.First, it views Allergan's portfolio of products, including Botox, as attractive. Second, it has the time to use the strong cash flow from Humana to pay off its Allergan acquisition. Once Humana faces fierce competition from generics, AbbVie will have paid off much of the debt related to the AGN buyout. And in a few years time, Allergan's drugs in the development pipeline will be ready for market.AbbVie's long-term future planning through the AGN acquisition makes AbbVie stock appealing for dividend-income investors. Even though shares rose from a $62.66 52-week low to $71.55, the stock still pays a dividend that yields 6%.At a Sep. 10 Healthcare Conference, AbbVie reiterated its commitment to cut debt and to continue growing its dividend. It will also allocate some cash for smaller mid- to late-state pipeline opportunities. Management has a good handle on integrating Allergan into its business but it will not let its existing pipeline suffer in any way.ABBV trades at an ~10% discount to the analyst price target of $79, but I think the AGN acquisition brings ABBV far more upside than that. Innoviva (INVA)Innoviva (NASDAQ:INVA) is another stock in the drug space whose large drop starting in late January continued throughout 2019. The stock may not yet be done falling. Why not?The fell began when the FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo.Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to buy now.Innoviva shares trended lower throughout 2019, as the stock lost $3 on its stock price by late-July. Investors sold the stock following the company's weak Q2 report. Innoviva reported Glaxo (NYSE:GSK) royalties falling 18% to $313.9 million. Overall, there was a net income decline of 31% (an EPS of $0.34).In its press release, the company said:"Management and the board continue to examine potential strategic actions to maximize future shareholder value." * 7 Momentum Stocks to Buy On the Dip Innoviva incurred expenses related to the evaluation of strategic options. But it will need to deliver on better shareholder value to attract stock buyers. Vodafone (VOD)Telecom stocks were out of favor heading into 2019. Now, telecom stocks are no longer out of favor. But Vodafone (NASDAQ:VOD), which after cratering in May, has just barely climbed back to it's pre-Christmas levels. So VOD is definitely still an undervalued stock.On July 26, Vodafone reported revenue stabilizing, falling just 2.3% Y/Y. The results sent VOD stock up 9% on the day. And ever since the stock bottomed at $16, it continues to run higher, closing recently at close to $20. In the fiscal Q1 2020 report, Vodafone said it enjoyed record low mobile contract churn. The deepening customer engagement will only strengthen as the telecom company launches 5G in all major EU markets.Service revenue in Q1 was mostly flat, down 0.2% and 0.5 pp sequentially.Simplifying the mobile plan offering will likely lead to higher revenue growth ahead. For example, Vodafone migrated 500,000 SIMs to a new unlimited offer. This will also increase ARPU and keep customers from switching to competitor services.Vodafone shares pay a dividend yield of 5.2%. If Vodafone grows its U.K. business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva and AbbVie.The post 5 Undervalued Stocks to Buy appeared first on InvestorPlace.

  • Moody's

    HCP, Inc. -- Moody's assigns P-2 rating to HCP's new commercial paper program and affirms existing ratings

    Moody's Investors Service ("Moody's") has assigned a Prime-2 (P-2) short-term rating to HCP, Inc's $1 billion senior unsecured commercial paper (CP) program in the U.S. Concurrently, Moody's also affirmed all existing ratings of HCP, including its Baa1 senior unsecured debt rating. HCP's P-2 short-term rating reflects the healthcare REIT's strong liquidity position supported by its large unsecured revolving credit facility with a total capacity of $2.5 billion. The CP notes will be issued by HCP, Inc. and rank pari-passu with the REIT's other unsecured senior debt.

  • Dow Jones Today: Fed Obliges, Stocks Don’t
    InvestorPlace

    Dow Jones Today: Fed Obliges, Stocks Don’t

    As was widely expected, the Federal Reserve lowered interest rates today by 25 basis points, but that wasn't enough to spark upside for equities. Nor was it enough for President Donald Trump who criticized the Fed for lacking "sense" and "vision" because it didn't lower rates by 50 basis points.Source: rafapress / Shutterstock.com Three Fed governors voted against today's rate cut, prompting some investors to express concern about the path forward."In determining the timing and size of future adjustments to the target range for the federal funds rate, the Committee will assess realized and expected economic conditions relative to its maximum employment objective and its symmetric 2 percent inflation objective," the Federal Open Market Committee wrote in a statement.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis assessment will take into account a wide range of information, including measures of labor market conditions, indicators of inflation pressures and expectations, and readings on financial and international developments.So today the Nasdaq Composite slipped 0.1% while the S&P 500 added just 0.03%. The Dow Jones Industrial Average gained 0.1%. In late trading, half of the Dow stocks were pointed higher. The only sector in the U.S. that closed higher today was, unsurprisingly, utilities. Small Winners CircleThere weren't many Dow winners today and among that small group, the gains were, well, small. One surprise was JPMorgan Chase (NYSE:JPM). Financial services stocks usually benefit from higher interest rates, and JPM and its rival banks have recently been complaining about the effects lower rates have on their net interest margins. In late trading JPM was the only financial services name in the Dow trading higher. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Another surprise, though of the disappointing variety, was Merck (NYSE:MRK). This Dow component barely nudged higher despite some encouraging news about its Keytruda cancer treatment. Regulators in Australia, Canada and the U.S. approved Keytruda to treat advanced endometrial carcinoma.This is significant news, but the stock barely moved higher today. Hey, it's not everyday three major developed markets approve a cancer treatment on the same day."Merck said regulators approved the use of Keytruda with a drug called Lenvima, discovered by the Japanese company Eisai (OTCMKTS:ESALY), to treat some instances of advanced endometrial carcinoma, a serious condition for which patients currently have few options," Josh Nathan-Kazis wrote for Barron's.Procter & Gamble (NYSE:PG) was a Dow winner today, and like the others, it was in modest fashion. P&G is one of the Dow's best-performing names this year. And some traders are getting bullish about options on the consumer goods giant's shares. Apple, AgainYes, Apple (NASDAQ:AAPL) has been making a lot of appearances here in recent days -- and the iPhone maker is back today. Wedbush released a note earlier today forecasting 185 million in iPhone 11 shipments for fiscal 2020. Analysts also wrote that pre-orders for the phone in the U.S. have been strong.Up nearly 8% this month, Apple has been one of the best-performing Dow stocks in September. Bottom Line on the Dow Jones TodayIt's clear that market participants are focusing on the Fed's division. However, because the central bank did not cut by 50 basis points today, it has another 25 basis point cut in its back pocket. Chairman Jerome Powell overtly said that the Fed can deploy more rate reductions if the economy sours, which he doesn't see happening right now.Speaking of the economy, the Fed upped its 2019 gross domestic product forecast to growth of 2.2%. That's up slightly from June's estimate of 2.1%. For now, the central bank is standing firm on its forecast of 2% GDP growth in 2020.As of this writing, Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars * 5 Stocks to Buy With Great Charts * 5 Goldman Sachs Stocks to Buy with Over 20% Upside Potential The post Dow Jones Today: Fed Obliges, Stocks Don't appeared first on InvestorPlace.

  • 3 Large-Cap Dividend Stocks to Buy After Fed Cuts Interest Rates for Second Time
    Zacks

    3 Large-Cap Dividend Stocks to Buy After Fed Cuts Interest Rates for Second Time

    We searched, using our Zacks Stock Screener, for large-cap dividend stocks investors might want to buy after the U.S. Federal Reserve cut interest rates for the second time...

  • 17 Consumer Staples Stocks to Take the Edge Off Your Portfolio
    Kiplinger

    17 Consumer Staples Stocks to Take the Edge Off Your Portfolio

    Consumer staples stocks have largely fallen off the radar in recent months. Investors have been much more focused on growth as corporate earnings have pleasantly surprised, the U.S.-China trade spat showed signs of hope and the Federal Reserve decided to keep interest rates steady.Naturally, these more defensive companies haven't been especially red-hot of late. Consumer staples stocks have lagged the marketwide bounce that took shape beginning in late December. But with many other sectors starting to feel the weight of unwieldy gains, and with China trade talks yet again hitting turbulence, the sector might be ready to heat up again.Steve Azoury, founder of financial planning firm Azoury Financial, says, "Consumer staples, the products that people use every day, will always be a big part of America's economy." "The trick," he adds, is identifying the companies that "will stay innovative and update their products and services to excite their customers, and thus the stock prices for investors."Here are 17 of the best consumer staples stocks to invest in at the moment. While some of these are blue-chip stocks that should ring a bell, others are lesser-known companies that serve as the backbone of brands you may be more familiar with. Almost all of them provide varying levels of dividend income. SEE ALSO: 57 Dividend Stocks You Can Count On

  • 3 Blue-Chip Stocks for a Market Slowdown
    TipRanks

    3 Blue-Chip Stocks for a Market Slowdown

    The global economy is starting to look a little shaky. Between the US-China trade tensions and now the Iranian-sponsored attacks on Saudi Arabian oil output, the pressures on the world system of trade and commerce are increasing. As CLSA’s Eric Fishwick said, “Trade both ways has slowed… the trade wars are definitely having an impact.” And in an effort to calm markets after the drone attack on his company’s largest facility, Saudi Aramco CEO Amin Nasser said, “We have enough oil products to supply the local market.”After posting losses on Monday, both the S&P 500 and the Dow Jones were up slightly on Tuesday. The S&P gained 0.26%, while the Dow added 0.13%. A look at the charts, however, shows that the sharp gains the markets have posted since August 23 have slowed and levelled off. Investors are watching the news and getting nervous.A wise investor will move to protect his portfolio, and we’ve found three Strong Buy stocks in the TipRanks database to do just that. These are large-cap health insurers, offering a product that remains in high demand no matter what the economic conditions, and generating high returns through share appreciation over the long-run. They are not cheap stocks, but they are classic defensive plays for an uncertain market environment. Anthem, Inc.With 40 million members, Anthem (ANTM – Get Report) is the largest managed care company in the Blue Cross Blue Shield network. It is the largest health insurer in California, the country’s largest state-wide market. ANTM shares are up 123% over the past five years, and the company’s dividend, while yielding a modest 1.24%, pays out an appreciable $3.20 per share annually.Anthem’s earnings reflect the company’s strong position in the health care market. In the second quarter, Anthem reported a net profit of $1.14 billion on quarterly revenues of $25.47 billion. EPS, at $4.64, was in line with the expected $4.62. Both profits and EPS were up year-over-year; net profits by 8.5% and EPS by 9%.Robust earnings and a solid position in its industry prompted Deutsche Bank analyst George Hill to start coverage of this stock with a Buy rating. He set a $323 price target, and noted, “The company's execution has been strong recently, even though we see some implementation risk [from] relatively lower exposure to the faster-growing segments of the market.” Hill’s price target suggests an upside potential of 25%.ANTM stock has a unanimous Buy consensus from the Street; 7 analysts have given this company a Buy in the past three months. Shares sell for $257, and the average price target of $345 implies a potential upside of 34%. Cigna Holding CompanyWith 5-year growth of 75%, and a Q2 earnings positive surprise of 13%, Cigna (CI – Get Report) is another solid performer in the health insurance industry. The company offers medical and dental, as well as accident, disability, and life insurance products around the world.Oppenheimer analyst Michael Wiederhorn, who has a 65% success rate with his stock recommendations, sees CI as a compelling buy. His price target of $254 suggests an impressive upside of 57%. In his comments, Wiederhorn states, “The [business] environment has certainly changed, with regulatory pressure affecting all ends of the pharmaceutical supply chain, but he believes the depressed multiples are well overdone.”Analyst George Hill, quoted above, also likes CI, enough to initiate coverage with a Buy rating. He writes, “The company's PBM segment does not contain the significant short-term earnings risk implied by the steep discount of the stock price. We believe its core commercial MCO and the perceived cross sales benefit could drive its multiple expansion.” Hill’s $207 price target implies an upside of 28%.Like Anthem, Cigna has a unanimous consensus rating of Strong Buy – in the last three months, the stock has been given 8 buy ratings. Cigna shares sell for $161, making it significantly less expensive than Anthem or UnitedHealth (see below), and its average price target of $214 gives the stock a 32% upside potential. UnitedHealth Group, Inc.UnitedHealth (UNH – Get Report) benefits from scale – it is the world’s largest health insurer and boasts over 115 million customers. Its 2018 revenue totaled over $225 billion, with over $17 billion realized in profits. More recently, UNH posted a 3.9% positive earnings surprise on Q2 EPS of $3.60. While the company’s growth has slowed in the past year, sheer scale ensures that it will remain profitable. The strong dividend, paying out $4.32 per share annually, makes this stable stock a favorite for return-minded investors.Continued profitability lies behind 4-star analyst A. J. Rice’s optimism on the stock. The Credit Suisse analyst gives UNH a buy rating with a $293 price target. Rice says of UNH, “The company gave the impression that the moderation in enrollment growth it’s seeing this year was largely expected... However, it also stressed that its goal of 13-16% EPS growth is a long-term target implying that 2020 is an unlikely timeframe to see such substantial improvements."Our current 2020 estimates anticipate 10% Y/Y growth. If UNH posts modest upside relative to our Q3 and Q4 2019 estimates, our 2020 $16.30 EPS est could then represent roughly 8-10% growth. This type of growth seems a reasonable initial target.” Rice’s price target suggests a potential upside of 26% for UNH shares. He has a 63% success rate with his recommendations on this stock.Overall, UNH holds a Strong Buy from the analyst consensus, with 10 buys and 2 holds given in the past three months. Shares in UNH sell for $232, making it the most expensive of the stocks in this list. The $298 price target suggests an upside of 28%.Visit TipRanks’ Trending Stocks page and find out what else the Street’s top analysts are looking at.

  • Establishment Labs Poised to Capitalize on Allergan Breast Implant Issues
    GuruFocus.com

    Establishment Labs Poised to Capitalize on Allergan Breast Implant Issues

    Costa Rican company’s technology believed to cause fewer complications Continue reading...

  • Leisure & Recreation Services Industry Prospects Look Dim
    Zacks

    Leisure & Recreation Services Industry Prospects Look Dim

    Leisure & Recreation Services Industry Prospects Look Dim

  • Morningstar

    13 Stocks to Own

    In Steal Like an Artist, author (and artist) Austin Kleon argues that nothing is completely original--we learn by copying. Kleon isn't suggesting that plagiarism is OK. Rather, he tells readers that they should collect good ideas and allow themselves to be influenced by them.

  • Procter & Gamble (PG) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Procter & Gamble (PG) Outpaces Stock Market Gains: What You Should Know

    Procter & Gamble (PG) closed the most recent trading day at $121.13, moving +1.15% from the previous trading session.

  • Could Algernon Pharmaceuticals Inc.'s (CNSX:AGN) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Algernon Pharmaceuticals Inc.'s (CNSX:AGN) Investor Composition Influence The Stock Price?

    The big shareholder groups in Algernon Pharmaceuticals Inc. (CNSX:AGN) have power over the company. Insiders often own...